> top > projects > Inflammaging > docs > PubMed:23704994 > annotations
Inflammaging  

PubMed:23704994 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-111 Sentence denotes Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study.
T1 0-111 Sentence denotes Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study.
T2 112-123 Sentence denotes BACKGROUND:
T2 112-123 Sentence denotes BACKGROUND:
T3 124-261 Sentence denotes Patients with chronic kidney disease (CKD) have high cardiovascular mortality and morbidity associated with increased arterial stiffness.
T3 124-261 Sentence denotes Patients with chronic kidney disease (CKD) have high cardiovascular mortality and morbidity associated with increased arterial stiffness.
T4 262-388 Sentence denotes Plasma aldosterone levels are increased in CKD, and aldosterone has been found to increase vascular inflammation and fibrosis.
T4 262-388 Sentence denotes Plasma aldosterone levels are increased in CKD, and aldosterone has been found to increase vascular inflammation and fibrosis.
T5 389-511 Sentence denotes It was hypothesized that aldosterone receptor inhibition with eplerenone could reduce arterial stiffness in CKD stage 3-4.
T5 389-511 Sentence denotes It was hypothesized that aldosterone receptor inhibition with eplerenone could reduce arterial stiffness in CKD stage 3-4.
T6 512-525 Sentence denotes STUDY DESIGN:
T6 512-525 Sentence denotes STUDY DESIGN:
T7 526-574 Sentence denotes The design was randomized, open, parallel group.
T7 526-574 Sentence denotes The design was randomized, open, parallel group.
T8 575-652 Sentence denotes Measurements of arterial stiffness markers were undertaken at weeks 1 and 24.
T8 575-652 Sentence denotes Measurements of arterial stiffness markers were undertaken at weeks 1 and 24.
T9 653-666 Sentence denotes INTERVENTION:
T9 653-666 Sentence denotes INTERVENTION:
T10 667-744 Sentence denotes 24 weeks of add-on treatment with 25-50 mg eplerenone or standard medication.
T10 667-744 Sentence denotes 24 weeks of add-on treatment with 25-50 mg eplerenone or standard medication.
T11 745-754 Sentence denotes OUTCOMES:
T11 745-754 Sentence denotes OUTCOMES:
T12 755-829 Sentence denotes Primary outcome parameter was carotid-femoral pulse wave velocity (cfPWV).
T12 755-829 Sentence denotes Primary outcome parameter was carotid-femoral pulse wave velocity (cfPWV).
T13 830-953 Sentence denotes Secondary outcomes were augmentation index (AIx), ambulatory arterial stiffness index (AASI) and urinary albumin excretion.
T13 830-953 Sentence denotes Secondary outcomes were augmentation index (AIx), ambulatory arterial stiffness index (AASI) and urinary albumin excretion.
T14 954-962 Sentence denotes RESULTS:
T14 954-962 Sentence denotes RESULTS:
T15 963-1042 Sentence denotes Fifty-four CKD patients (mean eGFR 36 mL/min/1.73 m(2), SD 11) were randomized.
T15 963-1042 Sentence denotes Fifty-four CKD patients (mean eGFR 36 mL/min/1.73 m(2), SD 11) were randomized.
T16 1043-1082 Sentence denotes Forty-six patients completed the trial.
T16 1043-1082 Sentence denotes Forty-six patients completed the trial.
T17 1083-1175 Sentence denotes The mean difference in cfPWV changes between groups was 0.1 m/s (95%CI: -1.0, 1.3), P = 0.8.
T17 1083-1175 Sentence denotes The mean difference in cfPWV changes between groups was 0.1 m/s (95%CI: -1.0, 1.3), P = 0.8.
T18 1176-1256 Sentence denotes The mean difference in AIx changes between groups was 4.4% (0.1, 8.6), P = 0.04.
T18 1176-1256 Sentence denotes The mean difference in AIx changes between groups was 4.4% (0.1, 8.6), P = 0.04.
T19 1257-1291 Sentence denotes AASI was unchanged in both groups.
T19 1257-1291 Sentence denotes AASI was unchanged in both groups.
T20 1292-1421 Sentence denotes The ratio of change in urinary albumin excretion in the eplerenone group compared to the control was 0.61 (0.37, 1.01), P = 0.05.
T20 1292-1421 Sentence denotes The ratio of change in urinary albumin excretion in the eplerenone group compared to the control was 0.61 (0.37, 1.01), P = 0.05.
T21 1422-1568 Sentence denotes Four patients were withdrawn from the eplerenone group including three because of possible side effects; one was withdrawn from the control group.
T21 1422-1568 Sentence denotes Four patients were withdrawn from the eplerenone group including three because of possible side effects; one was withdrawn from the control group.
T22 1569-1638 Sentence denotes Mild hyperkalemia was seen on three occasions and was easily managed.
T22 1569-1638 Sentence denotes Mild hyperkalemia was seen on three occasions and was easily managed.
T23 1639-1651 Sentence denotes LIMITATIONS:
T23 1639-1651 Sentence denotes LIMITATIONS:
T24 1652-1705 Sentence denotes The full planned number of patients was not attained.
T24 1652-1705 Sentence denotes The full planned number of patients was not attained.
T25 1706-1808 Sentence denotes The duration of the trial may have been too short to obtain full effect of eplerenone on the arteries.
T25 1706-1808 Sentence denotes The duration of the trial may have been too short to obtain full effect of eplerenone on the arteries.
T26 1809-1821 Sentence denotes CONCLUSIONS:
T26 1809-1821 Sentence denotes CONCLUSIONS:
T27 1822-1907 Sentence denotes Add-on treatment with eplerenone in CKD stage 3-4 did not significantly reduce cfPWV.
T27 1822-1907 Sentence denotes Add-on treatment with eplerenone in CKD stage 3-4 did not significantly reduce cfPWV.
T28 1908-1993 Sentence denotes There may be beneficial vascular effects leading to attenuated pulse wave reflection.
T28 1908-1993 Sentence denotes There may be beneficial vascular effects leading to attenuated pulse wave reflection.
T29 1994-2023 Sentence denotes Treatment was well-tolerated.
T29 1994-2023 Sentence denotes Treatment was well-tolerated.
T30 2024-2043 Sentence denotes TRIAL REGISTRATION:
T30 2024-2043 Sentence denotes TRIAL REGISTRATION:
T31 2044-2074 Sentence denotes ClinicalTrials.govNCT01100203.
T31 2044-2074 Sentence denotes ClinicalTrials.govNCT01100203.